Systemic Lupus Erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by immune dysregulation, persistent inflammation, and progressive organ damage. Affecting millions worldwide—primarily women of reproductive age—SLE remains one of the most complex autoimmune conditions to diagnose and manage. Its symptoms can mimic numerous disorders, earning it the reputation as “the great imitator.”
Recent scientific advances have significantly improved diagnostic accuracy, treatment outcomes, and long-term patient survival. Yet, SLE continues to impose profound physical, psychological, and economic burdens on patients and their families. Understanding the disease’s mechanisms, risk factors, clinical presentation, and treatment options is essential for effective long-term management.
This article presents a comprehensive, evidence-based overview of SLE, combining current scientific literature with insights from detailed medical lectures, including the uploaded material by Dr. Waqas Fazal.
What Is Systemic Lupus Erythematosus (SLE)?
SLE is a systemic autoimmune disorder in which the immune system mistakenly attacks the body’s own tissues, producing autoantibodies that cause widespread inflammation.
It may involve virtually any organ, including:
-
Skin
-
Joints
-
Kidneys
-
Heart
-
Lungs
-
Blood cells
-
Nervous system
The hallmark feature of SLE is the formation of immune complexes (antigen–antibody complexes) that deposit in tissues and trigger a Type III hypersensitivity reaction, leading to chronic inflammation.
Epidemiology and Risk Factors
-
Female-to-male ratio: ~10:1
-
Most common in women aged 15–45
-
Higher prevalence in African-American, Hispanic, and Asian populations
-
Family history and genetic markers (notably HLA-DR2 and HLA-DR3) increase risk
Environmental Triggers
-
Ultraviolet (UV) light
-
Smoking
-
Epstein–Barr virus
-
Silica exposure
-
Certain medications (hydralazine, procainamide, isoniazid)
These triggers can activate the immune system—especially in genetically predisposed individuals—leading to self-reactive antibody formation.
Pathophysiology of SLE
SLE begins with cell injury, often triggered by UV radiation or infections. Damaged cell nuclei release:
-
Nuclear DNA
-
Histones
-
Other nuclear proteins
In SLE, the body mistakenly identifies these components as foreign, producing antinuclear antibodies (ANA) targeting nuclear material.
Immune Mechanisms Involved
-
Formation of immune complexes (antibody + nuclear antigen)
-
Activation of complement system
-
Recruitment of inflammatory cells
-
Tissue damage and organ dysfunction
Complement deficiency—particularly low C3 and C4—limits clearance of immune complexes, worsening the disease.
Clinical Manifestations of SLE
SLE varies widely between patients. Symptoms may occur in flares followed by periods of remission.
1. Constitutional Symptoms
-
Fever
-
Fatigue
-
Weight loss
-
Malaise
These symptoms are often the earliest and most common presentation.
2. Musculoskeletal Symptoms
-
Arthritis
-
Arthralgia
-
Joint stiffness
Unlike rheumatoid arthritis, SLE does not cause joint deformity.
3. Skin Manifestations
-
Malar rash (butterfly rash) – spares the nasolabial folds (classic sign)
-
Discoid rash – scarring, chronic
-
Photosensitivity
-
Alopecia – non-scarring
4. Mucosal Involvement
-
Painless oral ulcers (distinguishing feature)
5. Raynaud’s Phenomenon
Fingers turn pale → blue → red when exposed to cold or stress.
6. Renal Involvement (Lupus Nephritis)
One of the most serious complications, characterized by:
-
Proteinuria
-
Hematuria
-
Hypertension
-
Risk of kidney failure
Kidney involvement is a major cause of morbidity and mortality in SLE.
7. Cardiopulmonary Involvement
-
Pericarditis
-
Myocarditis
-
Libman–Sacks endocarditis (noninfectious vegetations)
-
Pleuritis
-
Pulmonary hypertension
8. Neurological Symptoms
-
Seizures
-
Psychosis
-
Cognitive dysfunction
-
Headache
-
Cerebritis
Symptoms correlate with the presence of anti-neuronal antibodies.
9. Hematologic Abnormalities
-
Anemia
-
Leukopenia
-
Thrombocytopenia
-
Hemolysis
10. Antiphospholipid Syndrome (APS)
Some SLE patients develop APS, leading to:
-
Excessive clotting
-
Recurrent miscarriages
-
Stroke risk
Diagnosis of SLE
Diagnosis uses a combination of clinical criteria and laboratory results.
1. Screening Test
✔ ANA (Antinuclear Antibody) – Highly sensitive (98%)
A titer ≥1:80 supports evaluation for autoimmune disease.
4. [English (auto-generated)] S…
2. Specific Antibody Tests
-
Anti-dsDNA – correlates strongly with lupus nephritis
-
Anti-Smith (Sm) – most specific test for SLE
3. Complement Levels
-
Low C3 and C4 indicate active disease activity
4. Urinalysis
-
Proteinuria
-
Hematuria
-
Cellular casts
5. Kidney Biopsy
Gold standard for diagnosing lupus nephritis subtypes.
